Inventor · disambiguated record
William Dall'Acqua
Also filed as: DALL ACQUA WILLIAM · DALL ACQUA WILLIAM F · DALLACQUA WILLIAM
21 granted patents·28 pending applications·1,682 citations·filing 2001–2024
97Inventor score
Top patents by PatentIndex Score
49 records- 0199US7704497B2Molecules with extended half-lives, compositions and uses thereofMEDIMMUNE LLC·Filed 2007·Granted Apr 27, 2010·94 cites·49 claims
- 0299US7670600B2Molecules with extended half-lives, compositions and uses thereofMEDIMMUNE LLC·Filed 2006·Granted Mar 2, 2010·230 cites·26 claims
- 0399US7658921B2Molecules with extended half-lives, compositions and uses thereofMEDIMMUNE LLC·Filed 2007·Granted Feb 9, 2010·185 cites·14 claims
- 0499US7083784B2Molecules with extended half-lives, compositions and uses thereofMEDIMMUNE INC·Filed 2001·Granted Aug 1, 2006·704 cites·31 claims
- 0598US8323962B2Molecules with extended half-lives, compositions and uses thereofDALL ACQUA WILLIAM·Filed 2011·Granted Dec 4, 2012·107 cites·20 claims
- 0698US8012476B2Molecules with extended half-lives, compositions and uses thereofMEDIMMUNE LLC·Filed 2010·Granted Sep 6, 2011·55 cites·28 claims
- 0797US8475792B2Molecules with extended half-lives, compositions and uses thereofMEDIMMUNE LLC·Filed 2012·Granted Jul 2, 2013·49 cites·20 claims
- 0895US8697396B2Modulation of antibody effector function by hinge domain engineeringDALL ACQUA WILLIAM·Filed 2011·Granted Apr 15, 2014·40 cites·10 claims
- 0995US8309690B2Integrated approach for generating multidomain protein therapeuticsALLAN CHRISTIAN·Filed 2006·Granted Nov 13, 2012·87 cites·25 claims
- 1093US8795661B2Molecules with extended half-lives, compositions and uses thereofMEDIMMUNE LLC·Filed 2013·Granted Aug 5, 2014·16 cites·24 claims
- 1193US8323653B2Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseDAMSCHRODER MELISSA·Filed 2007·Granted Dec 4, 2012·32 cites·9 claims
- 1292US8883992B2Humanized anti-CD19 antibodiesMEDIMMUNE LLC·Filed 2012·Granted Nov 11, 2014·11 cites·9 claims
- 1391US8008443B2Modulation of antibody effector function by hinge domain engineeringMEDIMMUNE LLC·Filed 2006·Granted Aug 30, 2011·25 cites·8 claims
- 1490US9562100B2Molecules with extended half-lives, compositions and uses thereofMEDIMMUNE LLC·Filed 2014·Granted Feb 7, 2017·9 cites·30 claims
- 1587US2024417460A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2024·Application pending·0 cites
- 1686US9896505B2Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseMEDIMMUNE LLC·Filed 2014·Granted Feb 20, 2018·5 cites·8 claims
- 1784US7371383B2Recombinant anti-interleukin-9 antibodiesMEDIMMUNE INC·Filed 2003·Granted May 13, 2008·21 cites·44 claims
- 1883US8507656B2Stabilized angiopoietin-2 antibodies and uses thereofBEDIAN VAHE·Filed 2009·Granted Aug 13, 2013·6 cites·15 claims
- 1982US10011660B2Molecules with reduced effector function and extended half-lives, compositions, and uses thereofMEDIMMUNE LLC·Filed 2013·Granted Jul 3, 2018·5 cites·47 claims
- 2076US2024124612A1Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic propertiesMEDIMMUNE LLC·Filed 2023·Application pending·0 cites
- 2173US2021061906A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2020·Application pending·0 cites
- 2268US11767369B2Molecules with altered neonate Fc receptor binding having enhanced therapeutic and diagnostic propertiesMEDIMMUNE LLC·Filed 2019·Granted Sep 26, 2023·0 cites·26 claims
- 2368US8775090B2Crystals and structure of a human IgG Fc variant with enhanced FcRn bindingOGANESYAN VAHEH·Filed 2009·Granted Jul 8, 2014·1 cites·14 claims
- 2465US2010098708A1Methods of preventing and treating rsv infections and related conditionsMEDIMMUNE LLC·Filed 2009·Application pending·0 cites
- 2563US2018273621A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2018·Application pending·0 cites
- 2658US10329345B2Stabilized angiopoietin-2 antibodies and uses thereofMEDIMMUNE LTD·Filed 2016·Granted Jun 25, 2019·0 cites·15 claims
- 2757US2014171623A1Modulation Of Antibody Effector Function By Hinge Domain EngineeringMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 2857US2014302058A1Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseasesMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 2956US2006115485A1Methods of preventing and treating RSV infections and related conditionsMEDIMMUNE INC·Filed 2005·Application pending·0 cites
- 3055US2008299134A1Recombinant Anti-Interleukin-9 AntibodiesMEDIMMUNE INC·Filed 2008·Application pending·0 cites
- 3153US2013280251A1Stabilized Angiopoietin-2 Antibodies And Uses ThereofBEDIAN VAHE·Filed 2013·Application pending·0 cites
- 3252US2025270325A1Stabilized igg4 antibodies and uses thereofMEDIMMUNE LLC·Filed 2021·Application pending·0 cites
- 3352US2017101468A1Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseasesMEDIMMUNE LTD·Filed 2016·Application pending·0 cites
- 3451US2017073397A1MrkA Polypeptides, Antibodies, and Uses ThereofMEDIMMUNE LLC·Filed 2016·Application pending·0 cites
- 3551US2017267780A1Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic propertiesMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
- 3651US2006019342A1Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesisMEDIMMUNE INC·Filed 2005·Application pending·0 cites
- 3751US2011158985A1Methods of preventing and treating rsv infections and related conditionsMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 3851US2011077383A1Hinge domain engineeringMEDIMMUNE LLC·Filed 2008·Application pending·0 cites
- 3950US2014170142A1Molecules With Extended Half-Lives And Uses ThereofMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 4049US2011091992A1CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANTMEDIMMUNE LLC·Filed 2008·Application pending·0 cites
- 4149US2011008329A1Methods of Treating RSV Infections And Related ConditionsMEDIMMUNE LLC·Filed 2008·Application pending·0 cites
- 4249US2018258178A1Molecules with Reduced Effector Function and Extended Half-Lives, Compositions, and Uses ThereofMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 4348US2010143254A1Molecules with reduced half-lives, compositions and uses thereofMEDIMMUNE LLC·Filed 2007·Application pending·0 cites
- 4447US2009220527A1Affinity optimized epha2 agonistic antibodies and methods of use thereofMEDIMMUNE LLC·Filed 2006·Application pending·0 cites
- 4547US2019062411A1Mrka polypeptides, antibodies, and uses thereofMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 4647US2010145028A1Increasing The Production Of Recombinant Antibodies In Mammalian Cells By Site-Directed MutagenesisMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 4743US2006121042A1Modulation of antibody specificity by tailoring the affinity to cognate antigensMEDIMMUNE INC·Filed 2005·Application pending·0 cites
- 4842US2005181479A1Periplasmic expression of antibodies using a single signal sequenceMEDIMMUNE INC·Filed 2005·Application pending·0 cites
- 4939US2012134984A1Molecules with extended half-lives and uses thereofLUBMAN OLGA·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when William Dall'Acqua files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →